Central regulation of blood pressure by the mineralocorticoid receptor

Molecular and Cellular Endocrinology

Volumn 350, Issue 2, 2012, Pages 289-298

  Gomez Sanchez, Elise P ^a,b   Gomez Sanchez, Celso E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Brain; Corticosterone; Cortisol; Hypertension; Mineralocorticoid receptor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ANGIOTENSIN II; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CYCLOOXYGENASE 2; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; HYDROCORTISONE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; OUABAIN; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE SYNTHESIS; AMYGDALOID NUCLEUS; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BRAIN STEM; CEREBELLUM; CHOROID PLEXUS; COGNITION; DEPRESSION; GENE EXPRESSION; GENETIC POLYMORPHISM; HEMODYNAMICS; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MINERALOCORTICOID RECEPTOR GENE; NONHUMAN; OBESITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; SALT INTAKE; SUBCOMMISSURAL ORGAN; SYMPATHETIC TONE; THALAMUS;

ANIMALS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; HUMANS; HYPERTENSION; LIGANDS; POLYMORPHISM, GENETIC; PROTEIN BINDING; RECEPTORS, MINERALOCORTICOID;

EID: 84856351941     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.005     Document Type: Review

References (157)

1. Bealer S.L. Anteroventral third ventricle periventricular tissue contributes to cardiac baroreflex responses. Clin. Exp. Pharmacol. Physiol. 2000, 27:460-464.
2. Berecek K.H., Murray R.D., Gross F. Significance of sodium, sympathetic innervation and central adrenergic structures on renal vascular responsiveness in DOCA-treated rats. Circ. Res. 1980, 47:675-683.
3. Berry C., Murphy N.F., De Vito G., Galloway S., Seed A., Fisher C., Sattar N., Vallance P., Hillis W.S., McMurray J. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur. J. Heart Fail. 2007, 9:429-434.
4. Birmingham M.D., Stumpf W.E., Sar M. Nuclear localization of aldosterone in rat brain cells assessed by autoradiography. Experientia 1979, 35:1240-1241.
5. Birmingham M.K., Sar M., Stumpf W.E. Localization of aldosterone and corticosterone in the central nervous system, assessed by quantitative autoradiography. Neurochem. Res. 1984, 9:333-350.
6. Blaustein M.P., Hamlyn J.M. Pathogenesis of essential hypertension. A link between dietary salt and high blood pressure. Hypertension 1991, 18:III184-III195.
7. Blaustein M.P., Hamlyn J.M. Signaling mechanisms that link salt retention to hypertension: endogenous ouabain, the Na(+) pump, the Na(+)/Ca(2+) exchanger and TRPC proteins. Biochim. Biophys. Acta 2010, 1802:1219-1229.
8. Bogdan R., Perlis R.H., Fagerness J., Pizzagalli D.A. The impact of mineralocorticoid receptor ISO/VAL genotype (rs5522) and stress on reward learning. Genes Brain Behav. 2010, 9:658-667.
9. Brody M.J. Central nervous system and mechanisms of hypertension. Clin. Physiol. Biochem. 1988, 6:230-239.
10. Brody M.J., Fink G.D., Buggy J., Haywood J.R., Gordon F.J., Johnson A.K. The role of the anteroventral third ventricle (AV3V) region in experimental hypertension. Circ. Res. 1978, 43:2-13.
11. Brody M.J., Varner K.J., Vasquez E.C., Lewis S.J. Central nervous system and the pathogenesis of hypertension. Sites and mechanisms. Hypertension 1991, 18:III7-III12.
12. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V., Fabbri A., Zennaro M.C., Feve B. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011, 152:113-125.
13. Coleman T.G., Grange H.J., Guyton A.C. Whole-body autoregulation and hypertension. Circ. Res. 1971, 28(29):11-76.
14. Conn J.W. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 1955, 45:3-7.
15. Connell J.M., Davies E. The new biology of aldosterone. J. Endocrinol. 2005, 186:1-20.
16. Daniel K.R., Wells G., Stewart K., Moore B., Kitzman D.W. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest. Heart Fail. 2009, 15:68-74.
17. De Kloet E.R. Brain corticosteroid receptor balance and homeostatic control. Front. Neuroendocrinol. 1991, 12:95-164.
18. De Kloet E.R. Hormones and the stressed brain. Ann. N. Y. Acad. Sci. 2004, 1018:1-15.
19. De Kloet E.R., Versteeg D.H.G., Kovacs G.L. Aldosterone blocks the response to corticosterone in the raphe-hippocampal serotonin system. Brain Res. 1983, 264:323-327.
20. Diaz R., Brown R.W., Seckl J.R. Distinct ontogeny of glucocorticoid and mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase types I and II mRNAs in the fetal rat brain suggest a complex control of glucocorticoid actions. J. Neurosci. 1998, 18:2570-2580.
21. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H.S., Barthel A., Hauner H., McCann S.M., Scherbaum W.A., Bornstein S.R. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 2003, 100:14211-14216.
22. Emanuele E., Geroldi D., Minoretti P., Coen E., Politi P. Increased plasma aldosterone in patients with clinical depression. Arch. Med. Res. 2005, 36:544-548.
23. Fallo F., Federspil G., Veglio F., Mulatero P. The metabolic syndrome in primary aldosteronism. Curr. Hypertens. Rep. 2007, 9:106-111.
24. Farman N., Rafestin-Oblin M.E. Multiple aspects of mineralocorticoid selectivity. Am. J. Physiol.: Renal Physiol. 2001, 280:F181-F192.
25. Felder R.B. Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp. Physiol. 2010, 95:19-25.
26. Felder R.B., Francis J., Weiss R.M., Zhang Z.H., Wei S.G., Johnson A.K. Neurohumoral regulation in ischemia-induced heart failure. Role of the forebrain. Ann. N. Y. Acad. Sci. 2001, 940:444-453.
27. Felder R.B., Yu Y., Zhang Z.H., Wei S.G. Pharmacological treatment for heart failure: a view from the brain. Clin. Pharmacol. Ther. 2009, 86:216-220.
28. Francis J., Zhang Z.H., Weiss R.M., Felder R.B. Neural regulation of the proinflammatory cytokine response to acute myocardial infarction. Am. J. Physiol.: Heart Circ. Physiol. 2004, 287:H791-H797.
29. Frey F.J., Odermatt A., Frey B.M. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr. Opin. Nephrol. Hypertens. 2004, 13:451-458.
30. Funder J.W. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol. Cell. Endocrinol. 2004, 217:263-269.
31. Funder J.W. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007, 50:840-841.
32. Funder J.W. Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertens. Res. 2010, 33:872-875.
33. Funder J., Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996, 137:5264-5268.
34. Ganong W.F. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin. Exp. Pharmacol. Physiol. 2000, 27:422-427.
35. Geerling J.C., Loewy A.D. Aldosterone-sensitive neurons in the nucleus of the solitary tract: bidirectional connections with the central nucleus of the amygdala. J. Comp. Neurol. 2006, 497:646-657.
36. Geerling J.C., Loewy A.D. Aldosterone in the brain. Am. J. Physiol.: Renal Physiol. 2009, 297:F559-F576.
37. Geerling J.C., Kawata M., Loewy A.D. Aldosterone-sensitive neurons in the rat central nervous system. J. Comp. Neurol. 2006, 494:515-527.
38. Geerling J.C., Engeland W.C., Kawata M., Loewy A.D. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. J. Neurosci. 2006, 26:411-417.
39. Geerling J.C., Shin J.W., Chimenti P.C., Loewy A.D. Paraventricular hypothalamic nucleus: axonal projections to the brainstem. J. Comp. Neurol. 2010, 518:1460-1499.
40. Gekle M., Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflugers Arch. 2009, 458:231-246.
41. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., Meinke G., Tsai F.T., Sigler P.B., Lifton R.P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
42. Gilbert K.C., Brown N.J. Aldosterone and inflammation. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:199-204.
43. Gomez Sanchez E.P. Central mineralocorticoid receptors and cardiovascular disease. Neuroendocrinology 2009, 90:245-250.
44. Gomez-Sanchez E.P. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986, 118:819-823.
45. Gomez-Sanchez E.P. Dose-response studies of intracerebroventricular infusion of aldosterone in sensitized and nonsensitized rats. J. Hypertens. 1988, 6:437-442.
46. Gomez-Sanchez E.P. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr. Opin. Nephrol. Hypertens. 2004, 13:191-196.
47. Gomez-Sanchez E.P. The mammalian mineralocorticoid receptor: tying down a promiscuous receptor. Exp. Physiol. 2010, 95:13-18.
48. Gomez-Sanchez E.P., Gomez-Sanchez C.E. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am. J. Physiol. 1992, 263:E1125-E1130.
49. Gomez-Sanchez E.P., Gomez-Sanchez C.E. Maternal hypertension and progeny blood pressure: role of aldosterone and 11β-HSD. Hypertension 1999, 33:1369-1373.
50. Gomez-Sanchez E.P., Gomez-Sanchez C.E. Is aldosterone synthesized in the CNS regulated and functional?. Trends Endocrinol. Metab. 2003, 14:444-446.
51. Gomez-Sanchez E.P., Fort C.M., Gomez-Sanchez C.E. Intracerebroventricular infusions of RU28318 blocks aldosterone-salt hypertension. Am. J. Physiol. 1990, 258:E482-E484.
52. Gomez-Sanchez E.P., Venkataraman M.T., Thwaites D. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 1990, 258:E649-E653.
53. Gomez-Sanchez E.P., Gomez-Sanchez C.E., Fort C. Immunization of Dahl SS/jr rats with a ouabain conjugate mitigates salt-induced hypertension. Am. J. Hypertens. 1994, 7:591-596.
54. Gomez-Sanchez C.E., Zhou M.Y., Cozza E.N., Morita H., Eddleman F.C., Gomez-Sanchez E.P. Corticosteroid synthesis in the central nervous system. Endocr. Res. 1996, 22:463-470.
55. Gomez-Sanchez C.E., Zhou M.Y., Cozza E.N., Morita H., Foecking M.F., Gomez-Sanchez E.P. Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138:3369-3373.
56. Gomez-Sanchez E.P., Ganjam V., Chen Y.J., Liu Y., Zhou M.Y., Toroslu C., Romero D.G., Hughson M.D., de Rodriguez A., Gomez-Sanchez C.E. Regulation of 11 beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol. Am. J. Physiol.: Endocrinol. Metab. 2003, 285:E272-E279.
57. Gomez-Sanchez E.P., Samuel J., Vergara G., Ahmad N. Effect of 3{beta}-hydroxysteroid dehydrogenase inhibition by trilostane on blood pressure in the Dahl salt-sensitive rat. Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2005, 288:R389-R393.
58. Gomez-Sanchez E.P., Ahmad N., Romero D.G., Gomez-Sanchez C.E. Is aldosterone synthesized within the rat brain?. Am. J. Physiol.: Endocrinol. Metab. 2005, 288:E342-E346.
59. Gomez-Sanchez C.E., de Rodriguez A.F., Romero D.G., Estess J., Warden M.P., Gomez-Sanchez M.T., Gomez-Sanchez E.P. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 2006, 147:1343-1348.
60. Gomez-Sanchez E.P., Romero D.G., de Rodriguez A.F., Warden M.P., Krozowski Z., Gomez-Sanchez C.E. Hexose-6-phosphate dehydrogenase and 11{beta}-hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology 2008, 149:525-533.
61. Gomez-Sanchez E.P., Gomez-Sanchez C.M., Plonczynski M., Gomez-Sanchez C.E. Aldosterone synthesis in the brain contributes to Dahl salt-sensitive rat hypertension. Exp. Physiol. 2010, 95:120-130.
62. Gomez-Sanchez C.E., Rossi G.P., Fallo F., Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm. Metab. Res. 2010, 42:374-381.
63. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr. Res. 1998, 24:789-796.
64. Gordon R.D., Bachmann A.W., Jackson R.V., Saar N. Increased sympathetic activity in renovascular hypertension in man. Clin. Exp. Pharmacol. Physiol. 1982, 9:277-281.
65. Gros R., Ding Q., Sklar L.A., Prossnitz E.E., Arterburn J.B., Chorazyczewski J., Feldman R.D. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011, 57:442-451.
66. Grossmann C., Gekle M. Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance. Steroids 2008, 73:973-978.
67. Grossmann C., Gekle M. New aspects of rapid aldosterone signaling. Mol. Cell. Endocrinol. 2009, 308:53-62.
68. Grundy H.M., Simpson S.A., Tait J.F. Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature 1952, 169:795-796.
69. Guyton A.C. Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am. J. Hypertens. 1989, 2:575-585.
70. Hall C.E., Hall O. Interaction between deoxycorticosterone treatment, fluid intake, sodium consumption, blood pressure, and organ changes in rats during drinking water, saline, or sucrose solution. J. Physiol. Pharmacol. 1969, 47:81-86.
71. Hamlyn J.M., Laredo J., Shah J.R., Lu Z.R., Hamilton B.P. 11-Hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann. N. Y. Acad. Sci. 2003, 986:685-693.
72. Hitomi H., Kiyomoto H., Nishiyama A., Hara T., Moriwaki K., Kaifu K., Ihara G., Fujita Y., Ugawa T., Kohno M. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007, 50:750-755.
73. Holmes M.C., Seckl J.R. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol. Cell. Endocrinol. 2006, 248:9-14.
74. Huang B.S., Leenen F.H. The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction. Curr. Heart Fail. Rep. 2009, 6:81-88.
75. Huang B.S., Yuan B., Leenen F.H. Chronic blockade of brain " ouabain" prevents sympathetic hyper-reactivity and impairment of acute baroreflex resetting in rats with congestive heart failure. Can. J. Physiol. Pharmacol. 2000, 78:45-53.
76. Huang B.S., White R.A., Jeng A.Y., Leenen F.H. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2009, 296:R994-R1000.
77. Jaffe I.Z., Mendelsohn M.E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ. Res. 2005, 96:643-650.
78. Janiak P.C., Lewis S.J., Brody M.J. Role of central mineralocorticoid binding sites in development of hypertension. Am. J. Physiol. 1990, 259:R1025-R1034.
79. Jones A.W., Hart R.G. Altered ion transport in aortic smooth muscle during deoxycorticosterone acetate hypertension in rats. Circ. Res. 1975, 37:333-341.
80. Kang Y.M., Zhang Z.H., Johnson R.F., Yu Y., Beltz T., Johnson A.K., Weiss R.M., Felder R.B. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ. Res. 2006, 99:758-766.
81. Karssen A.M., Meijer O.C., van der Sandt I.C., Lucassen P.J., de Lange E.C., de Boer A.G., de Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001, 142:2686-2694.
82. Karssen A.M., Meijer O., Pons D., De Kloet E.R. Localization of mRNA expression of P-glycoprotein at the blood-brain barrier and in the hippocampus. Ann. N. Y. Acad. Sci. 2004, 1032:308-311.
83. Kasama S., Toyama T., Sumino H., Matsumoto N., Sato Y., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., Kurabayashi M. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J. Nucl. Med. 2007, 48:1993-2000.
84. King S.R., Manna P.R., Ishii T., Syapin P.J., Ginsberg S.D., Wilson K., Walsh L.P., Parker K.L., Stocco D.M., Smith R.G., Lamb D.J. An essential component in steroid synthesis, the steroidogenic acute regulatory protein, is expressed in discrete regions of the brain. J. Neurosci. 2002, 22:10613-10620.
85. Klok M.D., Vreeburg S.A., Penninx B.W., Zitman F.G., de Kloet E.R., Derijk R.H. Common functional mineralocorticoid receptor polymorphisms modulate the cortisol awakening response: interaction with SSRIs. Psychoneuroendocrinology 2010, 36:484-494.
86. Knowlton A.I., Loeb E.N., et al. Desoxycorticosterone acetate studies on the reversibility of its effect on blood pressure and renal damage in rats. Endocrinology 1949, 45:435-445.
87. Kontak A.C., Wang Z., Arbique D., Adams-Huet B., Auchus R.J., Nesbitt S.D., Victor R.G., Vongpatanasin W. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 2010, 95:4756-4761.
88. Kuhlman D., Ragan C., Ferrebee J.W., Atchley D.W., Loeb R.F. Toxic effects of deoxycorticosterone esters in dogs. Science 1939, 90:496-497.
89. Langford H.G., Snavely J.R. Effect of DCA on development of renoprival hypertension. Am. J. Physiol. 1959, 196:449-450.
90. Lastra-Gonzalez G., Manrique-Acevedo C., Sowers J.R. The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update. Curr. Diab. Rep. 2008, 8:203-207.
91. Lombes M., Kenouch S., Souque A., Farman N., Rafestin-Oblin M.-E. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11β-hydroxysteroid dehydrogenase. Endocrinology 1994, 135:834-840.
92. Luft R., Sjogren B. The effect of desoxycorticosterone acetate and sodium chloride on blood pressure and renal function. Acta Endocrinol. (Copenh.) 1949, 3:56-70.
93. Luther, J.M., Luo, P., Kreger, M.T., Brissova, M., Dai, C., Whitfield, T.T., Kim, H.S., Wasserman, D.H., Powers, A.C., Brown, N.J., 2011. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia (Epub ahead of print).
94. Macdonald J.E., Kennedy N., Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90:765-770.
95. MacKenzie S.M., Clark C.J., Fraser R., Gomez-Sanchez C.E., Connell J.M.C., Davies E. Expression of 11b-hydroxylase and aldosterone synthase genes in rat brain. J. Mol. Endocrinol. 2000, 24:321-328.
96. MacKenzie S.M., Clark C.J., Ingram M.C., Lai M., Seckl J., Gomez-Sanchez C.E., Fraser R., Connell J.M., Davies E. Corticosteroid production by fetal rat hippocampal neurons. Endocr. Res. 2000, 26:531-535.
97. McManus F., MacKenzie S.M., Freel E.M. Central mineralocorticoid receptors, sympathetic activity, and hypertension. Curr. Hypertens. Rep. 2009, 11:224-230.
98. Meijer O.C., Steenbergen P.J., De Kloet E.R. Differential expression and regional distribution of steroid receptor coactivators SRC-1 and SRC-2 in brain and pituitary. Endocrinology 2000, 141:2192-2199.
99. Mellon S.H. Neurosteroids: biochemistry, modes of action and clinical relevance. J. Clin. Endocrinol. Metab. 1994, 78:1003-1008.
100. Miyajima E., Yamada Y., Yoshida Y., Matsukawa T., Shionoiri H., Tochikubo O., Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991, 17:1057-1062.
101. Monahan K.D., Leuenberger U.A., Ray C.A. Aldosterone impairs baroreflex sensitivity in healthy adults. Am. J. Physiol.: Heart Circ. Physiol. 2007, 292:H190-H197.
102. Mosso L.M., Carvajal C.A., Maiz A., Ortiz E.H., Castillo C.R., Artigas R.A., Fardella C.E. A possible association between primary aldosteronism and a lower beta-cell function. J. Hypertens. 2007, 25:2125-2130.
103. Mulrow P.J. Angiotensin II and aldosterone regulation. Regul. Pept. 1999, 80:27-32.
104. Newton-Cheh C., Guo C.Y., Gona P., Larson M.G., Benjamin E.J., Wang T.J., Kathiresan S., O'Donnell C.J., Musone S.L., Camargo A.L., Drake J.A., Levy D., Hirschhorn J.N., Vasan R.S. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007, 49:846-856.
105. Nicholls M.G., Espiner E.A., Ikram H., Maslowski A.H., Hamilton E.J., Bones P.J. Hormone and blood pressure relationships in primary aldosteronism. Clin. Exp. Hypertens. A: Theory Pract. 1984, 6:1441-1458.
106. Nishi M., Tanaka M., Matsuda K., Sunaguchi M., Kawata M. Visualization of glucocorticoid receptor and mineralocorticoid receptor interactions in living cells with GFP-based fluorescence resonance energy transfer. J. Neurosci. 2004, 24:4918-4927.
107. Ota K., Katafuchi T., Takaki A., Hori T. AV3V neurons that send axons to hypothalamic nuclei respond to the systemic injection of IL-1beta. Am. J. Physiol. 1997, 272:R532-R540.
108. Pascual-Le Tallec L., Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol. Endocrinol. 2005, 19:2211-2221.
109. Penfornis P., Viengchareun S., Le Menuet D., Cluzeaud F., Zennaro M.C., Lombes M. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am. J. Physiol.: Endocrinol. Metab. 2000, 279:386-394.
110. Pietranera L., Saravia F.E., McEwen B.S., Lucas L.L., Johnson A.K., De Nicola A.F. Changes in Fos expression in various brain regions during deoxycorticosterone acetate treatment: relation to salt appetite, vasopressin mRNA and the mineralocorticoid receptor. Neuroendocrinology 2001, 74:396-406.
111. Pitt B., Zannad F., Cody R., Castaigne A.P.A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. New Engl. J. Med. 1999, 341:709-717.
112. Raab W., Humphreys R.J., Lepeschkin E. Potentiation of pressor effects of nor-epinephrine and epinephrine in man by desoxycorticosterone acetate. J. Clin. Invest. 1950, 29:1397-1404.
113. Robson A.C., Leckie C.M., Seckl J.R., Holmes M.C. 11-Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Mol. Brain Res. 1998, 61:1-10.
114. Rodbard S., Freed S.C. The effect of desoxycorticosterone acetate on the blood pressure of the dog. Endocrinology 1942, 30:365-368.
115. Roland B.L., Li K.X., Funder J.W. Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology 1995, 136:4697-4700.
116. Sakai R.R., McEwen B.S., Fluharty S.J., Ma L.Y. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 2000, 57:1337-1345.
117. Savory J.G., Prefontaine G.G., Lamprecht C., Liao M., Walther R.F., Lefebvre Y.A., Hache R.J. Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces. Mol. Cell. Biol. 2001, 21:781-793.
118. Shekhtman E., Geerling J.C., Loewy A.D. Aldosterone-sensitive neurons of the nucleus of the solitary tract: multisynaptic pathway to the nucleus accumbens. J. Comp. Neurol. 2007, 501:274-289.
119. Shin J.W., Geerling J.C., Loewy A.D. Inputs to the ventrolateral bed nucleus of the stria terminalis. J. Comp. Neurol. 2008, 511:628-657.
120. Shin J.W., Geerling J.C., Loewy A.D. Vagal innervation of the aldosterone-sensitive HSD2 neurons in the NTS. Brain Res. 2009, 1249:135-147.
121. Simpson S.A., Tait J.F., Wettstein A., Neher R., von Euw J., Schindler O., Reichstein T. Konstitution des aldosterons, des neuen mineralocorticoids. Experientia 1953, 10:132-133.
122. Smith A.D., Brands M.W., Wang M.H., Dorrance A.M. Obesity-induced hypertension develops in young rats independently of the renin-angiotensin-aldosterone system. Exp. Biol. Med. (Maywood) 2006, 231:282-287.
123. Sonino N., Fallo F., Fava G.A. Psychological aspects of primary aldosteronism. Psychother. Psychosom. 2006, 75:327-330.
124. Stanisic V., Lonard D.M., O'Malley B.W. Modulation of steroid hormone receptor activity. Prog. Brain Res. 2010, 181:153-176.
125. Steiger M., Reichstein T. Desoxy-corticosterone (21-oxy-progesterone). Aus d-3-oxo-etiocholensäure. Helv. Chim. Acta 1937, 20:1164.
126. Stein M.K., Loewy A.D. Area postrema projects to FoxP2 neurons of the pre-locus coeruleus and parabrachial nuclei: brainstem sites implicated in sodium appetite regulation. Brain Res. 2010, 1359:116-127.
127. Stumpf W.E., Sar M. Glucocorticosteroids and mineralocorticosteroid hormone target sites in the brain. Autoradiographic studies with corticosterone, aldosterone, deoxycorticosterone. Interaction Within the Brain-Pituitary-Adrenocortical System 1979, 137-147. Academic Press.
128. Sukor N., Kogovsek C., Gordon R.D., Robson D., Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 2010, 95:1360-1364.
129. Tait J.F., Tait S.A.S. A steroid memoir: a decade (or more) of electrocortin (aldosterone). Steroids 1988, 51:213-250.
130. Tait S.A., Tait J.F., Coghlan J.P. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol. Cell. Endocrinol. 2004, 217:1-21.
131. Todd-Turla K.M., Schnermann J., Fejes-Toth G., Naray-Fejes-Toth A., Smart A., Killen P.D., Briggs J.P. Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am. J. Physiol. 1993, 264:F781-F791.
132. Trapp T., Rupprecht R., Castren M., Reul J.M., Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron 1994, 13:1457-1462.
133. Tripodi G., Citterio L., Kouznetsova T., Lanzani C., Florio M., Modica R., Messaggio E., Hamlyn J.M., Zagato L., Bianchi G., Staessen J.A., Manunta P. Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. Am. J. Hypertens. 2009, 22:357-363.
134. Tsugita M., Iwasaki Y., Nishiyama M., Taguchi T., Shinahara M., Taniguchi Y., Kambayashi M., Nishiyama A., Gomez-Sanchez C.E., Terada Y., Hashimoto K. Glucocorticoid receptor plays an indispensable role in mineralocorticoid receptor-dependent transcription in GR-deficient BE(2)C and T84 cells in vitro. Mol. Cell. Endocrinol. 2009, 302:18-25.
135. Ulick S., Wang J.Z., Blumenfeld J.D., Pickering T.G. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 1992, 74:963-967.
136. Van Leeuwen N., Caprio M., Blaya C., Fumeron F., Sartorato P., Ronconi V., Giacchetti G., Mantero F., Fernandes-Rosa F.L., Simian C., Peyrard S., Zitman F.G., Penninx B.W., de Kloet E.R., Azizi M., Jeunemaitre X., Derijk R.H., Zennaro M.C. The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension 2010, 56:995-1002.
137. Vanatta J.C., Cottle K.E. Effect of desoxycorticosterone acetate on the peripheral vascular reactivity of dogs. Am. J. Physiol. 1955, 151:119-122.
138. Viengchareun S., Le Menuet D., Martinerie L., Munier M., Pascual-Le Tallec L., Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl. Recept. Signal. 2007, 5:e012.
139. Wang J., Yu L., Solenberg P.J., Gelbert L., Geringer C.D., Steinberg M.I. Aldosterone stimulates angiotensin-converting enzyme expression and activity in rat neonatal cardiac myocytes. J. Card. Fail. 2002, 8:167-174.
140. Wang H., Huang B.S., Leenen F.H. Brain sodium channels and ouabainlike compounds mediate central aldosterone-induced hypertension. Am. J. Physiol.: Heart Circ. Physiol. 2003, 285:H2516-H2523.
141. Ward K.R., Bardgett J.F., Wolfgang L., Stocker S.D. Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 2011, 57:435-441.
142. Weber K.T. Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone. J. Lab. Clin. Med. 2003, 142:71-82.
143. Whalen E.J., Schoorlemmer G.H., Beltz T.G., Johnson A.K., Lewis S.J. Effects of chronic lesions of the anteroventral region of the third ventricle on cardiac beta-adrenoceptor function in conscious rats. Brain Res. 2001, 913:82-85.
144. Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010, 52:401-409.
145. Wickert L., Selbig J. Structural analysis of the DNA-binding domain of alternatively spliced steroid receptors. J. Endocrinol. 2002, 173:429-436.
146. Wyrwoll, C.S., Holmes, M.C., Seckl, J.R., 2010. 11β-hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front. Neuroendocrinol (Epub ahead of print).
147. Xue B., Beltz T.G., Yu Y., Guo F., Gomez-Sanchez C.E., Hay M., Johnson A.K. Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. Am. J. Physiol.: Heart Circ. Physiol. 2011, 300:H555-H564.
148. Yagi S., Akaike M., Aihara K., Iwase T., Yoshida S., Sumitomo-Ueda Y., Ikeda Y., Ishikawa K., Matsumoto T., Sata M. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens. Res. 2011, 34:74-78.
149. Yang J., Chang C.Y., Safi R., Morgan J., McDonnell D.P., Fuller P.J., Clyne C.D., Young M.J. Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol. Endocrinol. 2011, 25:32-43.
150. Ye P., Kenyon C.J., MacKenzie S.M., Seckl J.R., Fraser R., Connell J.M., Davies E. Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 2003, 144:3321-3328.
151. Ye P., Kenyon C.J., Mackenzie S.M., Nichol K., Seckl J.R., Fraser R., Connell J.M., Davies E. Effects of ACTH, dexamethasone, and adrenalectomy on 11beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) gene expression in the rat central nervous system. J. Endocrinol. 2008, 196:305-311.
152. Yongue B.G., Roy E.J. Endogenous aldosterone and corticosterone in brain cell nuclei of adrenal-intact rats: regional distribution and effects of physiological variations in serum steroids. Brain Res. 1987, 436:49-61.
153. Young M.J. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2008, 17:174-180.
154. Yu Y., Zhang Z.H., Wei S.G., Serrats J., Weiss R.M., Felder R.B. Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension 2010, 55:652-659.
155. Zennaro M.C., Souque A., Viengchareun S., Poisson E., Lombes M. A new human mr splice variant is a ligand-independent transactivator modulating corticosteroid action. Mol. Endocrinol. 2001, 15:1586-1598.
156. Zhang Z.H., Kang Y.M., Yu Y., Wei S.G., Schmidt T.J., Johnson A.K., Felder R.B. 11Beta-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension 2006, 48:127-133.
157. Zhang Z.H., Yu Y., Wei S.G., Felder R.B. Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling. J. Hypertens. 2010, 28:806-816.